Headquarters: Hartum 19 , Har Hotzvim Industrial Park Jerusalem 9777518 Israel
Investor Relations: mailto:nimrod@gyntools.com
Description
Most women suffer from vaginitis at least once in their lifetime; however 50% of first clinic visits end with misdiagnosis, Driven by the belief that women’s diagnosis should be faster, more accurate, and accessible to all, we developed Gyni , a platform that redefines the diagnosis of vaginitis. We started commercializing Gyni in Europe & Israel.
Industry
Medical Devices
Year Founded
2016
Website
Ownership
Private
Chief Executive Officer
Nimrod Lev
Chairman of the Board
Meny Lev Sagie
Chief Financial Officer
Insider Ownership
Key Investors
Employee Count
3
Most Recent Raise (Date)
11-01-2022
Most Recent Round
We entered a $ 5 M round recently.
Total Capital Raised
Auditors
Investment Bankers
Law Firms
Matry, Meiri & Wacht
In the CEOs Own Words
Corporate Mission
Bring better diagnostic solutions that will improve women’s health, and become a world leader.
Proudest Accomplishment
Next Milestone
AMAR clearance, Pilot studies in Israeli HMOs & IDF. Commercialization.
Geographic Markets Served
AMAR clearance, Pilot studies in Israeli HMOs & IDF. Commercialization.
Growth Drivers
Awareness to women's health. Huge market that is looking for solutions.
Growth Headwinds
Local regulation and reimbursement terms slow us while entering new markets.
Indicia of Customer Satisfaction
Scalability
We can scale up production quickly, since we are working with external subcontractors who does the production.
Workforce
Focus of Recruitment
Research and Development
We have several projects, supported with IP, in our pipeline.
Patent Count
Gyni - In-clinic sample collector and scanner Patent Granted in USA, Israel & JP (11,346,850 / 253067 / 7187552 ) Pending (EU, CN) GYNI Home Patent Granted (USA 11,454,576) Pending multi national (EU, JP, CN, IN) Algorithms - un-patented to keep source code as exclusive company know-how. Proprietary DATA BASE of classified vaginitis images. GYNI™ – Trade Mark. (Cleared- USA, Europe, Switzerland).
Economic Sensitivity
GYNI is aimed for developed countries. Understanding that there's a need in developing regions, as well, we have GYNI ECO concept that will allow sales in low- income countries.